Sahpra news updates “South African Health Products Regulatory Authority”. Visit Sahpra website here or see the feed summary below.

  • Update: Feedback on SAHPRA’s EOIs and latest appointments
    The South African Health Products Regulatory Authority (SAHPRA) has published four (4) Expression of Interests (EOIs) since 2023, and these have all been closed. Updates on EOIs: Download PDF The post Update: Feedback on SAHPRA’s EOIs and latest appointments appeared first on SAHPRA. Read more »
  • Landmark agreement among Africa’s leading National Medicines Regulatory Authorities to foster collaboration
    Cairo, Egypt, 4 February 2025: The Africa Centres for Disease Control and Prevention (Africa CDC) and African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) are proud to announce the signing of a Memorandum of Understanding (MoU) among Africa’s WHO Maturity Level 3... The post Landmark agreement among… Read more »
  • South Africa-WHO gears up to map way forward to fight substandard and falsified medical products
    Pretoria – The leading agencies, the South African Health Products Regulatory Authority (SAHPRA) and the National Department of Health (NDoH) with identified key stakeholders for the National Action Plan (NAP) are in a three-day workshop this week (4-6 February 2025) to pilot the World Health... The post South Africa-WHO gears… Read more »
  • SAHPRA clarifies the benefits and risks of medroxyprogesterone acetate
    Pretoria, 17 January 2025 – The South African Health Products Regulatory Authority (SAHPRA) has recommended that the product information of medroxyprogesterone acetate (MPA)-containing products be amended by updating the safety warnings to include the potential risk of meningioma. MPA is a synthetic oral and injectable... The post SAHPRA clarifies the… Read more »
  • Telephone system has been restored
    The South African Health Products Regulatory Authority (SAHPRA) wishes to inform stakeholders that the organisation’s telephone system has been restored. SAHPRA apologises for any inconvenience this may have caused. The post Telephone system has been restored appeared first on SAHPRA. Read more »
  • Temporary telephone system disruption
    The South African Health Products Regulatory Authority (SAHPRA) wishes to inform stakeholders that the organisation is currently experiencing a technical issue with its telephone system, which is affecting both outgoing and incoming calls. The Authority’s service provider is working diligently to resolve the issue as... The post Temporary telephone system… Read more »
  • SAHPRA Offices will be unavailable on 29 November 2024
    Please note that SAHPRA Head Office, including Cape Town and Durban Regional Offices will be unavilable today, 29 November 2024 due to the organisation’s Annual General Meeting. If you require assistance, please use applicable contacts from Key Contacts: https://www.sahpra.org.za/key-contacts/ The post SAHPRA Offices will be unavailable on 29 November 2024… Read more »
  • SAHPRA office closure during the 2024 festive season
    SAHPRA offices will be closed for the festive season from 12:00 on Tuesday, 24 December 2024 and will re-open on Monday, 06 January 2025. Please note: Submissions to SAHPRA New Medicine, Variation, License, Renewal Applications Applications/submissions via sFTP will continue however applications received after 20... The post SAHPRA office closure… Read more »
  • SAHPRA recalls a batch of YAZ Plus contraceptives due to a quality issue
    Pretoria, 21 November 2024 – The South African Health Products Regulatory Authority (SAHPRA) is aware of a quality issue in a batch of YAZ Plus contraceptives (Batch No. WEW96J distributed on 09 and 24 November 2023) which has resulted in the incorrect arrangement of tablets... The post SAHPRA recalls a… Read more »
  • SAHPRA’s position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified
    Pretoria, 08 November 2024 –The South African Health Products Regulatory Authority (SAHPRA) is concerned about the proliferation of falsified, compounded and substandard Glucagon-like Peptide (GLP-1)-containing products being made available to the public via websites, social media platforms and other informal channels. These pose a health... The post SAHPRA’s position on… Read more »

Daily Live is updated with the latest news

from Sahpra find out how to keep this page updated.